IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells

BMC Cancer

Volumn 1, Issue , 2001, Pages

  Barton, Beverly E ^a   Murphy, Thomas F ^a   Adem, Patricia ^a   Watson, Richard A ^a   Irwin, Robert J ^a   Huang, Hosea F ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; JANUS KINASE 2; LIPOCORTIN 5; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN ANTIBODY; STAT3 PROTEIN; ANTIINFLAMMATORY AGENT; DNA BINDING PROTEIN; ENZYME INHIBITOR; INTERLEUKIN 6 RECEPTOR; JAK2 PROTEIN, RAT; ONCOPROTEIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN, RAT; TRANSACTIVATOR PROTEIN; TYRPHOSTIN; TYRPHOSTIN AG-490;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIUM CELL; FLOW CYTOMETRY; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL LINE; DEXAMETHASONE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; EPITHELIAL CELLS; INTERLEUKIN-6; JANUS KINASE 2; MALE; PHENOTYPE; PHOSPHORYLATION; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 3042515162     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-1-19     Document Type: Article

References (42)

1. Brawer MK: Prostate cancer: where have we been, where we are, where we are going. World J. Surg 2000, 24:1200-1204
2. Tohyama N, Karasuyama H, Tada T: Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA. J. Exp. Med 1990, 171:389-400
3. Zhang X-G, Klein B, Bataille R: Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989, 74:11-13
4. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP: Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991, 77:587-593
5. Ensoli B, Barillari G, Gallo RC: Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol. Rev 1992, 127:147-155
6. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691
7. Huang Y-W, Vitetta ES: A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Hybridoma 1993, 12:621-630
8. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991, 78:1198-1204
9. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Can. Res 1993, 53:851-856
10. Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T: Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo 1992, 22:1989-1993
11. Haddad E, Paczeny S, Leblond V, Seigneurin J-M, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, de Ligny BH, Wijdenes J, Durandy A, Fischer A: Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001, 97:1590-1597
12. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 1993, 81:3357-3364
13. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S: Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med 1995, 182:243-248
14. Ihle JN: STATs and MAPKs: obligate or opportunistic partners in signaling. BioEssays 1996, 18:95-98
15. Imada K, Leonard WJ: The Jak-STAT pathway. Mol. Immunol 2000, 37:1-11
16. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro . Cancer Res 1997, 59:141-146
17. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW: Characterization of the role of IL-6 in the progression of prostate cancer. The Prostate 1999, 38:199-207
18. Boresellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N: Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostain M inhibits PC-3 cell growth and sensitizes the tumor cells to etopside and cisplatin-mediated cytotoxicity. Cancer 1999, 85:134-144
19. Borsellino N, Belidegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995, 55:4633-4639
20. Siegall CB, Nordan RP, Fitzgerald DJ, Pastan I: Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells. Mol. Cell. Biol 1990, 10:2443-2447
21. Chen T, Wang LH, Farrar WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cencer cells. Cancer Res 2000, 60:2132-2135
22. Siegsmund MJ, Yamazaki H, Pastan I: Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J. Urol 1994, 151:1396-1399
23. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB: Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 1994, 54:4313-3421
24. Danielpour D: Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a lumnal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J. Cell Science 1998, 112:169-179
25. Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D: The role of transforming growth factor-β1, -β2, -β3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J. Cell. Physiol 1998, 175:184-192
26. Hayward SW, Haughney PC, Lopes ES, Danielpour D, Cunha GR: The rat prostatic epithelial line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 1999, 39:205-212
27. Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, Campis J, Stavnezer E, Medrano EE: Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type β transforming growth factor. Proc. Natl. Acad. Sci. USA 2000, 97:5924-5929
28. Barton BE, Murphy TF: Constitutive expression of IL-6-like cytokines in normal bone marrow: Implications for myeloma pathophysiology. Cytokine 2000, 12:18-27
29. Ni Z, Lou W, Leman ES, Gao AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 2000, 60:
30. Bromberg J, JE DJ: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473
31. Sano S, Kira M, Takagi S, Yoshikawa K, Takeda J, Itami S: Two distinct signaling pathways in hair cycle induction: Stat3-dependent and - independent pathways. Proc. Natl. Acad. Sci. USA 2000, 97:13824-13829
32. Murakami-Mori K, Mori S, Taga T, Kishimoto T, Nakamura S: Enhancement of gp130-mediated tyrosine phosphorylation of STAT3 and its DNA-binding actibvity in dexamethasone-treated AIDS-associated Kaposi's sarcoma cells. J. Immunol 1997, 158:5518-5526
33. Foster CB, Lehmecher T, Samuels S, Stein S, F M, Metcalf JA, Wyvil K, Steinberg SA, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ: An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000, 96:2562-2567
34. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitski A, Kraker A, Krolewski JJ, Medvecsky P, Jove R: Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem 2000, 275:24935-24944
35. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr: Stat3 as an oncogene. Cell 1999, 98:295-293
36. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate 2000, 42:239-242
37. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K: Specific inhibition of STAT3 signal transduction by PIAS3. Science 1997, 278:1803-1805
38. Spiotto MT, Chung TDK: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000, 42:186-195
39. Aoki Y, Yarchoan R, Wyvill K, Okamoto S-i, Little RF, Tosato G: Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-liked disorders. Blood 2001, 97:2173-2176
40. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G: Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999, 94:2871-2879
41. Parravicini C, Lauri E, Baldini L, Neri A, Poli F, Sirchia G, Moroni M, Galli M, Corbellino M: Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science 1997, 278:1969-1973
42. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM, Fan S: Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001, 488:179-184